Tesamorelin

Tesamorelin (TH-9507) is a GHRH analogue and one of the few peptides with FDA approval. It was approved specifically to reduce excess abdominal fat in HIV patients with lipodystrophy — a condition where fat accumulates abnormally around the organs. Supplied as lyophilized powder with ≥98% purity (HPLC-verified).

How It Works

Tesamorelin stimulates the pituitary to release growth hormone. The resulting GH increase targets visceral fat — the deep abdominal fat surrounding organs — for breakdown and metabolism. It is selective for visceral fat over subcutaneous fat, which is unique among fat-reducing compounds.

Research Data

• FDA approval: Approved in 2010 (Egrifta®) for reduction of excess abdominal fat in HIV-associated lipodystrophy — supported by two large Phase 3 trials.
• Visceral fat reduction: Clinical trials showed an average 15% reduction in visceral adipose tissue over 26 weeks, compared to a 5% increase in the placebo group.
• Waist circumference: Reduced waist circumference by approximately 2-3 cm and improved the waist-to-hip ratio.
• IGF-1 elevation: Consistent with GH release, tesamorelin increases IGF-1 levels by 80-100% — providing both fat reduction and tissue-building effects.
• Body composition: Improvements in lean body mass and overall body composition were observed alongside fat reduction.
• Triglycerides: Significant reductions in triglyceride levels were reported, improving cardiovascular risk profiles.

Research Applications

• GHRH receptor pharmacology
• Visceral adipose tissue biology
• HIV-associated lipodystrophy and metabolic disorders
• Body composition and fat distribution studies

Product Specifications

• Purity: ≥98% (HPLC)
• Form: Lyophilized powder
• Solubility: Reconstitute in sterile bacteriostatic water

Storage & Handling

• Store lyophilized peptide at -20°C, protected from light and moisture.
• After reconstitution, aliquot and store at -20°C. Avoid repeated freeze-thaw cycles.

Disclaimer: This product is intended exclusively for laboratory and research purposes. It is not a drug, dietary supplement, or food product. Not for human or veterinary use.

What the Internet Says

This is what online communities discuss about this compound. Not medical advice, not a recommendation — just what people are saying. For laboratory research use only.

Community Buzz

Tesamorelin — called “Tesa” or “the belly fat peptide” — holds a special status in peptide communities: it’s one of the very few peptides that’s actually FDA-approved (as Egrifta, for HIV-related visceral fat). This gives it a legitimacy halo that other research peptides envy. The community zeroes in on one thing: its uncanny ability to target visceral fat — the deep belly fat that wraps around organs and resists diet and exercise. Clinical data showed ~15% reduction in visceral adipose tissue. On forums, users say things like “my stomach flattened without the scale moving.” In 2024-2026, Tesa exploded in popularity when people started stacking it with GLP-1 agonists — the GLP-1 strips overall weight while Tesa specifically attacks the stubborn belly.

Why People Are Interested

• Targets belly fat specifically. Not just general weight loss — the community swears Tesa goes after the deep, stubborn abdominal fat that diet alone can’t touch.
• Leans you out without muscle loss. Users report looking “leaner at the same weight” — less belly but preserved (or even improved) muscle definition.
• FDA-approved pedigree. Unlike most research peptides, Tesa has real human clinical data backing its safety and effectiveness profile. This matters a lot to cautious biohackers.
• Mental clarity improves. A newer community discovery — users report sharper focus and better memory. The GHRH receptor exists in the brain, so there may be a real mechanism.

Popular Combinations

• Tesamorelin + Ipamorelin (“Tesa/Ipa”): The dominant stack — Tesa provides sustained GHRH signaling, Ipamorelin adds clean GH pulses. Taken at night, 5 days on / 2 days off.
• Tesamorelin + Tirzepatide or Semaglutide: The “ultimate cut stack” — GLP-1 kills appetite, Tesa targets visceral fat. Hugely popular in 2024-2026.
• Tesamorelin + MOTS-C: Metabolic double threat — Tesa handles visceral fat via GH pathway, MOTS-C ramps up metabolism via AMPK.
• Tesamorelin + BPC-157 + TB-500: Recomp + repair — Tesa for fat loss and GH benefits, BPC/TB for tissue healing.

⚠️ Sourced from public forums (Reddit r/Peptides, r/Biohackers), fitness communities, and peptide blogs. Some users report joint stiffness at higher doses (especially in hands). Daily injection fatigue (5 nights/week) is a common complaint. Community protocols are experimental. This information is for awareness only.